BioMarin Pharmaceutical Inc.
BMRN
$58.58
$0.510.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 657.24M | 523.88M | 426.86M | 322.29M | 256.59M |
| Total Depreciation and Amortization | 83.25M | 91.15M | 96.43M | 99.68M | 106.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 318.91M | 286.71M | 265.95M | 223.09M | 195.42M |
| Change in Net Operating Assets | -292.62M | -201.47M | -216.40M | -230.36M | -229.50M |
| Cash from Operations | 766.77M | 700.26M | 572.84M | 414.70M | 328.86M |
| Capital Expenditure | -71.86M | -76.09M | -85.42M | -94.81M | -98.08M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.28M | 198.58M | 221.92M | 89.94M | 63.57M |
| Cash from Investing | 19.42M | 122.49M | 136.49M | -4.88M | -34.52M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -494.93M | -494.93M | -494.93M | -494.93M | 1.64M |
| Issuance of Common Stock | 20.37M | 42.08M | 49.28M | 56.22M | 55.78M |
| Repurchase of Common Stock | -61.91M | -66.39M | -77.56M | -76.57M | -75.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.18M | -3.20M | -3.24M | -3.19M | -2.35M |
| Cash from Financing | -539.65M | -522.43M | -526.45M | -518.47M | -20.13M |
| Foreign Exchange rate Adjustments | -4.88M | 1.49M | 4.83M | -1.32M | 3.55M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 241.67M | 301.81M | 187.72M | -109.97M | 277.77M |